Vitura Health Limited · ASX:VIT
Vitura Health — H1 FY2023 Earnings Presentation
27 slides from Vitura Health's earnings presentation, Feb 13, 2023
Slide 1: ASX Announcement: Investor Webinar
ASX ANNOUNCEMENT INVESTOR WEBINAR For personal use only 13 FEBRUARY 2023 Melbourne, Australia – Vitura Health Limited (ASX: VIT) (Vitura and Company) is pleased to provide details of an investor webinar that will be held at the time and date set out below at which the Company’s 2023 half-year result
Slide 2: About Vitura Health Limited
About Vitura Health Limited Vitura Health Limited (formerly Cronos Australia Limited) is listed on the ASX. • The Company’s wholly owned subsidiary, CDA Health Pty Ltd, operates the following For personal use only businesses: o Burleigh Heads Cannabis - operates the market leading prescriber, patien
Slide 3: For personal use only
For personal use only Investor Presentation February 2023 11
Slide 4: We Are Now Vitura
WE ARE NOW VITURA Ajuo Ssn feuosied 10}
Slide 5: Financial Performance
For personal use only FINANCIAL PERFORMANCE
Slide 6: Investment Highlights – H1 FY2023
Investment Highlights – H1 FY2023 Outstanding growth in H1 FY2023, extremely well positioned for the remainder of FY2023 Market leading, profitable and rapidly growing healthcare company with a deep moat around the CanView platform For personal use only Profitable, highly cash generative, dividend p
Slide 7: Financial Highlights – H1 FY2023
Financial Highlights – H1 FY2023 A record half year, with Gross Revenue annualizing at $115m+ and NPAT at $15m+ For personal use only Triple digit growth on all financial metrics in H1 FY2023 compared to H1 FY2022 H1 FY2023 Movement H1 FY2022 Gross Revenue $57.64m 111% $27.38 EBITDA $11.84m 128% $5.
Slide 8: Record months within the record half year of FY2023
Record months within the record half year of FY2023 An example of a record month in the half year is November 2022 with gross revenue of nearly $11m For personal use only While we saw growth in the half year, significant growth was seen MoM in November when we achieved an annual run rate of $130m+ i
Slide 9: Significant revenue growth continued over the half year
Significant revenue growth continued over the half year Record Revenue for Q2 FY2023 of $29.8m for CanView, an uplift of 10% QoQ, which has resulted in a quarterly compound growth rate of 31% over the previous 10 quarters For personal use only Quarterly revenue through CanView o Sales continue to gr
Slide 10: Key operational milestones achieved during the half year
Key operational milestones achieved during the half year CanView 2.0 rollout progress and Melbourne Distribution Centre commissioning For personal use only Significant progress being made operationally to continue to scale the business profitably and sustainably CanView 2.0 Rollout Progress Melbourn
Slide 11: The Strategic Priorities in FY2023 to deliver growth
The Strategic Priorities in FY2023 to deliver growth Leveraging a successful FY2022 and H1 FY2023, the Team has clear strategic priorities for execution to deliver growth in the scope and scale of Vitura’s performance and drive financial results For personal use only Growth Strategy Phase 1 – FY2022
Slide 12: We are an Australian market leader
We are an Australian market leader Backed by a market leading business model, financial strength and a large addressable market, Vitura is well positioned for further growth in the remainder of FY2023 and beyond For personal use only o Vitura Health has delivered outstanding, profitable growth in FH
Slide 13: Company Overview
For personal use only COMPANY OVERVIEW CanView – Australia’s largest and most trusted medicinal cannabis marketplace
Slide 14: The market we operate in is large and growing rapidly
The market we operate in is large and growing rapidly The medicinal cannabis market continues to grow rapidly in Australia, as cannabinoid therapies become mainstream for patients, prescribers and pharmacists For personal use only Number of active medicinal cannabis patients - Australia Australian m
Slide 15: We operate at the downstream end of the value chain
We operate at the downstream end of the value chain Vitura is focused on the high value, downstream end of the value chain for sustainable long-term growth and profitability For personal use only Finished Product Clinics and Distribution Genetics Cultivation Extraction Manufacturing Patient and Bran
Slide 16: What we do – a clear focus
What we do – a clear focus Laser focused on the CanView platform, products and our clinic businesses For personal use only Vitura Health delivers medicinal cannabis prescription, sales and distribution services for doctors, pharmacies and patients throughout Australia Platform and Products – CanView
Slide 17: The CanView platform
The CanView platform The CanView platform facilitates all aspects of the medicinal cannabis ecosystem for patients, prescribers, pharmacists and suppliers – with a clear Network Effect For personal use only Referred Patient Patient books a Prescriber appointment via CanView in person or via Teleheal
Slide 18: CanView for Patients
CanView for Patients CanView solves multiple problems for patients that were previously impossible, or very difficult to achieve, without the platform For personal use only The number of Patients on CanView has grown Cumulative patients Cumulative patient registered on CanView significantly with 32%
Slide 19: CanView for Prescribers
CanView for Prescribers Based on feedback, CanView makes prescribing for medical practitioners streamlined and underpins their compliance obligations for regulators, including AHPRA and the TGA For personal use only Quarter on quarter the number of Prescribers Cumulative Cumulative prescriber accoun
Slide 20: CanView for Pharmacies
CanView for Pharmacies CanView has integrated significant feedback from pharmacies, which saves them time, delivers on compliance and makes dispensing extremely efficient For personal use only CanView has onboarded more than 3,300+ Cumulative Cumulative pharmacies accounts on CanView Pharmacies in A
Slide 21: CanView for Suppliers
CanView for Suppliers Rather than waiting for monthly updates, CanView provides suppliers with real time data, transparency and forecasting insight For personal use only Nearly 30 of the leading suppliers are Quarterly unit sales through CanView onboarded on CanView, with unit sales Unit Q1 FY2021 –
Slide 22: Australia's leading suppliers have partnered with CanView
Australia’s leading suppliers have partnered with CanView CanView is trusted by Australia’s leading suppliers to sell and distribute the widest range of medicinal cannabis products available For personal use only Highly rigorous process to select and Consistency and continuity Investment in medical
Slide 23: The Team
The Team Strategy and execution focused We have assembled an experienced, commercially-focused team to execute on the strategy and create sustainable shareholder value over the long term. For personal use only Experienced Board combining deep business development, sales, distribution, branding and r
Slide 24: Appendices
For personal use only APPENDICES
Slide 25: Appendix – CanView Overview and Benefits
Appendix 1 – CanView Overview and Benefits CanView overview and benefits CanView delivers medicinal cannabis prescription, sales and distribution services for doctors, pharmacies and patients For personal use only throughout Australia Free to use | The platform is free for all users to register and
Slide 26: Disclaimer
Disclaimer The following disclaimer applies to this presentation (Presentation) You are therefore advised to read this disclaimer carefully before reading or making any other use of this Presentation or any For personal use only information contained in this Presentation. This Presentation has been
Slide 27: Vitura Health Limited
For personal use only VITURA HEALTH LIMITED ASX : VIT www.vitura.com.au info@vitura.com.au 1300 799 491